Fulcrum Therapeutics Inc (FULC) Reports Financial Results for Q4 and Full Year 2023 [Yahoo! Finance]
Fulcrum Therapeutics, Inc. (FULC)
Last fulcrum therapeutics, inc. earnings: 3/5 07:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Collaboration Revenue : Grew to $0.9 million in Q4 2023, but annual collaboration revenue decreased to $2.8 million from $6.3 million in 2022. R&D Expenses : Slightly increased to $19.0 million in Q4 2023, with a yearly decrease to $71.8 million from $76.8 million in 2022. G&A Expenses : Decreased marginally to $9.9 million in Q4 2023, remaining stable at $41.7 million annually. Net Loss : Improved to $24.8 million in Q4 2023, with annual net loss reducing to $97.3 million from $109.9 million in 2022. Warning! GuruFocus has detected 3 Warning Sign with FULC. Fulcrum Therapeutics Inc ( NASDAQ:FULC ) released its 8-K filing on February 27, 2024, detailing its financial results for the fourth quarter and full year of 2023. The clinical-stage biopharmaceutical company, known for its small molecule therapies aimed at treating genetically defined rare diseases, has reported a strengthened cash position and progress in its clinical programs, despite a mixed financial performance.
Show less
Read more
Impact Snapshot
Event Time:
FULC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FULC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FULC alerts
High impacting Fulcrum Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FULC
News
- Fulcrum Therapeutics, Inc. (NASDAQ: FULC) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $23.00 price target on the stock.MarketBeat
- Fulcrum Therapeutics, Inc. (NASDAQ: FULC) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $16.00 to $14.00. They now have an "outperform" rating on the stock.MarketBeat
- Fulcrum Therapeutics, Inc. (NASDAQ: FULC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock.MarketBeat
- Sanofi to make €1bn biomanufacturing investment in France [Yahoo! Finance]Yahoo! Finance
- Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely? [Yahoo! Finance]Yahoo! Finance
FULC
Earnings
- 5/13/24 - Beat
FULC
Sec Filings
- 5/13/24 - Form 10-Q
- 5/13/24 - Form 8-K
- 5/9/24 - Form 4
- FULC's page on the SEC website